4doq

Publication Abstract from PubMed

SLPI (secretory leukocyte protease inhibitor) is a 107-residue protease inhibitor which inhibits various serine proteases, including elastase, cathepsin G, chymotrypsin and trypsin. SLPI is obtained as a multiple inhibitor in lung defense and in chronic airway infection. X-ray crystal structures have so far reported that they are full-length SLPIs with bovine alpha-chymotrypsin and 1/2SLPI (recombinant C-terminal domain of SLPI; Arg58-Ala107) with HNE (human neutrophil elastase). To understand the role of this multiple inhibitory mechanism, the crystal structure of 1/2SLPI with porcine pancreas trypsin was solved and the binding modes of two other complexes compared. The Leu residue surprisingly interacts with the S1 site of trypsin, as with chymotrypsin and elastase. The inhibitory mechanism of 1/2SLPI using the wide primary binding site contacts (from P2' to P5) with various serine proteases is discussed. These inhibitory mechanisms have been acquired in the evolution of the protection system for acute inflammatory diseases.

Structure basis 1/2SLPI and porcine pancreas trypsin interaction.,Fukushima K, Kamimura T, Takimoto-Kamimura M J Synchrotron Radiat. 2013 Nov;20(Pt 6):943-7. doi: 10.1107/S090904951302133X., Epub 2013 Sep 29. PMID:24121345^[1]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.